PMID- 14519070
OWN - NLM
STAT- MEDLINE
DCOM- 20040719
LR  - 20191026
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 3
IP  - 7
DP  - 2003 Oct
TI  - Allogeneic immune replacement as cancer immunotherapy.
PG  - 1051-60
AB  - The graft-versus-leukaemia (GVL) reaction that occurs after allogeneic 
      haematopoietic cell transplantation (HCT) can cure patients with a variety of 
      haematological malignancies. A heightened appreciation of the GVL effect has 
      resulted in the development of reduced intensity transplant approaches, where 
      antitumour effects occur predominantly as a consequence of the transplanted donor 
      immune system. The recent success of these transplants in patients with acute and 
      chronic leukaemias has led to trials investigating for graft-versus-tumour (GVT) 
      effects in patients with treatment-refractory metastatic solid tumours. This 
      review discusses evidence that immune replacement following allogeneic HCT is a 
      potent form of cancer immunotherapy for patients with haematological and 
      non-haematological malignancies.
FAU - Chakrabarti, Sakti
AU  - Chakrabarti S
AD  - National Heart, Lung, and Blood Institute, Hematology branch, 9000 Rockville 
      Pike, Bethesda, Maryland 20892, USA.
FAU - Childs, Richard
AU  - Childs R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
SB  - IM
MH  - Animals
MH  - Graft vs Host Disease
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunotherapy/*trends
MH  - Leukemia/immunology/therapy
MH  - Neoplasms/*therapy
MH  - Transplantation, Homologous
RF  - 69
EDAT- 2003/10/02 05:00
MHDA- 2004/07/20 05:00
CRDT- 2003/10/02 05:00
PHST- 2003/10/02 05:00 [pubmed]
PHST- 2004/07/20 05:00 [medline]
PHST- 2003/10/02 05:00 [entrez]
AID - 10.1517/14712598.3.7.1051 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2003 Oct;3(7):1051-60. doi: 10.1517/14712598.3.7.1051.